Founded in 1991, Camurus has grown into a $4B biotech with two products in the market, a rich pipeline, and 290 employees.Fredrik explains how Camurus’ long-acting injections — part of its FluidCrystal technology — breathe new life into generic drugs, making it easier for patients to stick to their treatment regimen. This has applications in many diseases, including hormonal disorders and obesity, with new formulations of GLP-1 agonists.He also discusses how long-acting versions of buprenorphine can help patients to overcome opioid addiction and tackle the global opioid crisis.

---

Learn how YSDS helps move your most sensitive life sciences shipments worldwide, safely, on time, with full visibility at https://bit.ly/ysds-flotbio.

---

⭐️ ABOUT THE SPEAKER

Fredrik joined Camurus in 2002 as a member of the board and CEO in 2003. Before this, he was CEO of Heptahelix AB and a leading academic at Lund University and the University of Oxford.

🔗 LINKS MENTIONED

• Camurus’ website - https://www.camurus.com/
• Oczyesa’s approval - https://www.camurus.com/media/press-releases/2025/camurus-oczyesa-receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu/
• Brixadi’s approval - https://braeburnrx.com/media/press-releases/braeburns-brixadi-buprenorphine-extended-release-subcutaneous-injection-ciii-receives-fda-approval-for-moderate-to-severe-opioid-use-disorder
• Empire of Pain: The Secret History of the Sackler Dynasty - https://www.amazon.com/Empire-Pain-History-Sackler-Dynasty/dp/0385545681
• Camurus regains worldwide development and commercialization rights to CAM2029 from Novartis - https://www.camurus.com/media/press-releases/2018/camurus-regains-worldwide-development-and-commercialization-rights-to-cam2029-and-related-product-candidates/
• Camurus and Lilly enter collaboration and license agreement - https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/
• Nitazenes: Super-strength opioids spreading across Europe and North America - UN - https://www.bbc.com/news/articles/crgge1ez0r2o

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/fredrik-tiberg-camurus-opioid-crisis/

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

• Newsletter: http://eepurl.com/h_fnmH
• LinkedIn: https://www.linkedin.com/company/flot-bio/
• X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.

⏰ TIMESTAMPS

• [00:00:00] Intro
• [00:02:47] Camurus: the $4-billion powerhouse
• [00:08:25] The FluidCrystal technology
• [00:15:24] Buvidal tackles opioid addiction
• [00:26:05] Oczyesa’s commercial challenges
• [00:31:03] Metabolic programmes in progress
• [00:34:45] 4 years of profits
• [00:37:00] Solving the opioid crisis
• [00:46:44] Europe’s long-acting drugs scene
• [00:51:05] Fredrik Tiberg’s background
• [00:55:15] Quick-fire questions